At 3.9% CAGR, Middle East & Africa Sarcopenia Treatment Market is Projected to be Worth US$ 90.55 Million by 2030, says Business Market Insights

According to Business Market Insights' research, the Middle East & Africa sarcopenia treatment market was valued at US$ 66.59 million in 2022 and is expected to reach US$ 90.55 million by 2030, registering a CAGR of 3.9% from 2022 to 2030. Upsurge in geriatric population and rising awareness about sarcopenia are among the critical factors attributed to drive the Middle East & Africa sarcopenia treatment market growth.

The geriatric population is prone to sarcopenia, orthopedic disorders, metabolic disorders, and neurological disorders, among others. Sarcopenia is a geriatric illness characterized by a progressive loss of the mass and strength of skeletal muscles. It is associated with a higher risk of unfavorable health outcomes, e.g., falls, disabilities, institutionalization, poor quality of life, and mortality. The elderly populace is rising rapidly in developed countries. According to the World Health Organization (WHO), the aging population across the world is likely to rise from ~1 billion in 2019 to ~2.1 billion by 2050.

Aging results in a reduction in muscle mass as one of the major changes in body composition. A significant decline in food consumption among elderly people is one of the key factors causing the loss of muscle mass. According to the National Library of Medicine, people from the age group of 50-60 lose nearly 1.5% of muscle strength every year, while 1-2% of muscle mass is lost annually after the age of 60. Compared to general populations, elderly patients had a higher prevalence of sarcopenia. According to an article published in June 2023 in Elsevier, the prevalence of sarcopenia ranges from 18% in diabetic patients to 66% in those with incurable esophageal cancer. Hence, the rising elderly population contributes significantly to the sarcopenia treatment market growth.

On the contrary, unavailability of direct interventions hampers the growth of Middle East & Africa sarcopenia treatment market.

Based on treatment type, the Middle East & Africa sarcopenia treatment market is segmented into vitamin D and calcium supplement, protein supplement, vitamin B12 supplement, and others. The vitamin D and calcium supplement segment held 41.2% share of Middle East & Africa sarcopenia treatment market in 2022, amassing US$ 27.45 million. It is projected to garner US$ 39.88 million by 2030 to register 4.8% CAGR during 2022-2030.

In terms of distribution channel, the Middle East & Africa sarcopenia treatment market is segmented into pharmacies, retail channels, online channels, and others. The pharmacies segment held 39.4% share of Middle East & Africa sarcopenia treatment market in 2022, amassing US$ 26.27 million. It is anticipated to garner US$ 34.12 million by 2030 to expand at 3.3% CAGR during 2022-2030.

Based on country, the Middle East & Africa sarcopenia treatment market is categorized into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Our regional analysis states that South Africa captured 41.4% share of Middle East & Africa sarcopenia treatment market in 2022. It was assessed at US$ 27.55 million in 2022 and is likely to hit US$ 38.62 million by 2030, registering a CAGR of 4.3% during 2022-2030.

Key players operating in the Middle East & Africa sarcopenia treatment market are Abbott Laboratories, Bayer AG, Nestle Health Science SA, Novartis AG, Pfizer Inc, Sanofi SA, Amway Corp, and GSK Plc, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com